RECURSION PHARMACEUTICALS, INC. (RXRX) Earnings
RECURSION PHARMACEUTICALS, INC.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Aug 5, 2026
From the latest earnings 8-K
Revenue · FY2025
$74.68M
▲ 26.9%YoY
Diluted EPS · FY2025
$-1.44
▲ 14.8%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from RXRX's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $74.68M | -$644.76M | — | $-1.44 | -$378.28M | -867.9% | +26.9% |
| FY2024 | $58.84M | -$463.66M | — | $-1.69 | -$372.87M | -814.1% | +32.0% |
| FY2023 | $44.58M | -$328.07M | — | $-1.58 | -$299.74M | -785.3% | +11.9% |
| FY2022 | $39.84M | -$239.48M | — | $-1.36 | -$120.58M | -616.7% | +291.5% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 5, 2026 | 8-K (2.02) | 0001601830-26-000097EDGAR |
| May 6, 2026 | 8-K (2.02) | 0001601830-26-000077EDGAR |
| Feb 25, 2026 | 8-K (2.02) | 0001601830-26-000038EDGAR |
| Nov 5, 2025 | 8-K (2.02) | 0001601830-25-000164EDGAR |
| Aug 5, 2025 | 8-K (2.02) | 0001601830-25-000126EDGAR |
| May 5, 2025 | 8-K (2.02) | 0001601830-25-000074EDGAR |
| Feb 28, 2025 | 8-K (2.02) | 0001601830-25-000034EDGAR |
Earnings for companies related to RXRX
Never miss a RXRX filing.
Get an email when RXRX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Sep 16, 2026Source: SEC EDGAR.